WO2025003793 - ADAPTING ARRAY LAYOUTS TO ACCOUNT FOR TUMOR PROGRESSION
National phase entry:
Publication Number
WO/2025/003793
Publication Date
02.01.2025
International Application No.
PCT/IB2024/055224
International Filing Date
29.05.2024
Title **
[English]
ADAPTING ARRAY LAYOUTS TO ACCOUNT FOR TUMOR PROGRESSION
[French]
ADAPTATION DE DISPOSITIONS DE MATRICE POUR TENIR COMPTE DE LA PROGRESSION D'UNE TUMEUR
Applicants **
NOVOCURE GMBH
Inventors
NADAV, Shapira
BERGER, Brian
Priority Data
63/523,853
28.06.2023
US
18/675,714
28.05.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2078 | |
| EPO | Filing, Examination, Granting | 8141 | |
| Japan | Filing, Examination, Granting | 2170 | |
| South Korea | Filing, Examination, Granting | 2092 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
19,221
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
A computer-implemented method comprising: obtaining a three-dimensional model of a subject, the model comprising voxels; identifying a gross tumor volume for the three- dimensional model, the gross tumor volume representing a current location of a tumor in the subject; identifying a primary clinical target volume for the three-dimensional model, the primary clinical target volume having a larger volume than the gross tumor volume, the primary clinical target volume representing an approximation of the current location of the tumor in the subject; identifying a predictive clinical target volume for the three-dimensional model, the predictive clinical target volume having a larger volume than the primary clinical target volume, the predictive clinical target volume representing a predicted future location of the tumor in the subject; and selecting at least one transducer layout for delivering tumor treating fields to the subject based on the primary clinical target volume and the predictive clinical target volume.[French]
Procédé mis en œuvre par ordinateur qui comprend les étapes suivantes : obtention d'un modèle tridimensionnel d'un sujet, le modèle comprenant des voxels ; identification d'un volume de tumeur brut pour le modèle tridimensionnel, le volume de tumeur brut représentant un emplacement actuel d'une tumeur chez le sujet ; identification d'un volume cible clinique primaire pour le modèle tridimensionnel, le volume cible clinique primaire ayant un volume plus grand que le volume de tumeur brut, le volume cible clinique primaire représentant une approximation de l'emplacement actuel de la tumeur chez le sujet ; identification d'un volume cible clinique prédictif pour le modèle tridimensionnel, le volume cible clinique prédictif ayant un volume plus grand que le volume cible clinique primaire, le volume cible clinique prédictif représentant un emplacement futur prédit de la tumeur chez le sujet ; et sélection d'au moins une disposition de transducteurs pour administrer des champs de traitement de tumeur au sujet sur la base du volume cible clinique primaire et du volume cible clinique prédictif.